Editas Medicine says its ex vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies.
The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
FDA slaps clinical hold on Crispr Therapeutics and Vertex Pharmaceuticals' upcoming gene-editing trial.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
Gene editing offers near-limitless medical potential. The challenge is putting it into medical practice. So how is gene editing progressing, in terms of biotech pipelines, investment, and therapeutic approvals?
The hot gene editing company plans to raise a comparatively small amount of money in its IPO, when considering the amount of money it's raised privately.
CRISPR gene editing is heralded one of the most promising technologies today - and it's ramping up fast. Here's a commercial timeline - from just the past year.
Looks like the gene editing startup plans to start with simple gene editing techniques that focus heavily on diseases of the eye.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
Looks like CRISPR is headed to the clinic: Editas Medicine just announced that it'll bring this gene editing technology to human trials by 2017.
The market potential of CRISPR technology has been legitimized by Editas Medicine's impressive, $120 million fundraise. Here are six more biotechs shaping the CRISPR landscape look like now? And what other players are in this game?
Isn't Theranos supposed to be a smart company? The MIT Technology Review highlights each year what it considers the world's "smartest companies." Understandably, several have been left out.
An NIH study has shown that giving HIV drugs when patients are initially diagnosed with the disease is more effective than waiting for the white blood cell counts to drop.